Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$25.48 +0.7%	$23.84	$20.92 ▼ $42.48	$48.27B	N/A	259,911 shs	451,216 shs
MKKGY Merck KGaA	$26.33 +1.7%	$25.87	$24.32 ▼ $39.17	$17.01B	0.91	142,990 shs	94,453 shs
TAK Takeda Pharmaceutical	$15.50 +1.3%	$14.80	$12.80 ▼ $15.56	$49.33B	0.22	2.56 million shs	3.46 million shs
ZTS Zoetis	$156.32 +0.5%	$154.00	$139.70 ▼ $200.33	$69.28B	0.88	3.10 million shs	2.43 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-3.92%	+3.52%	+5.16%	-4.06%	-37.34%
MKKGY Merck KGaA	-0.87%	+0.09%	+0.29%	-0.56%	-31.85%
TAK Takeda Pharmaceutical	-1.16%	+3.32%	+5.08%	+4.94%	+2.38%
ZTS Zoetis	-0.77%	+1.52%	+2.84%	-4.56%	-14.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	2.9235 of 5 stars	0.0	3.0	2.5	0.0	1.7	0.0	3.1
TAK Takeda Pharmaceutical	1.5558 of 5 stars	0.0	3.0	2.5	0.0	3.3	0.0	0.6
ZTS Zoetis	4.8999 of 5 stars	3.3	5.0	4.2	0.4	3.1	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
MKKGY Merck KGaA	2.33	Hold	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
ZTS Zoetis	2.50	Moderate Buy	$202.43	29.50% Upside

Current Analyst Ratings Breakdown

Latest MKKGY, ZTS, TAK, and DSNKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	MKKGY Merck KGaA	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $215.00
8/8/2025	MKKGY Merck KGaA	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.90	$1.22 per share	20.95	$5.61 per share	4.54
MKKGY Merck KGaA	$22.57B	0.75	$8.23 per share	3.20	$50.22 per share	0.52
TAK Takeda Pharmaceutical	$30.09B	1.64	$3.18 per share	4.87	$14.89 per share	1.04
ZTS Zoetis	$9.26B	7.48	$7.05 per share	22.17	$11.23 per share	13.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	24.74	23.38	1.30	15.65%	17.92%	8.61%	10/30/2025 (Estimated)
MKKGY Merck KGaA	$3.00B	$2.38	11.06	12.84	3.21	13.49%	9.81%	5.73%	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.30	51.68	9.40	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.81	26.91	23.16	2.52	27.83%	56.90%	19.54%	11/3/2025 (Estimated)

Latest MKKGY, ZTS, TAK, and DSNKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	MKKGY Merck KGaA	$0.51	$0.57	+$0.06	$0.57	$5.34 billion	$6.11 billion
8/5/2025	Q2 2025	ZTS Zoetis	$1.62	$1.76	+$0.14	$1.61	$2.41 billion	$2.46 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.28	1.10%	N/A	27.18%	N/A
MKKGY Merck KGaA	$0.33	1.25%	N/A	13.87%	N/A
TAK Takeda Pharmaceutical	$0.55	3.55%	N/A	183.33%	N/A
ZTS Zoetis	$2.00	1.28%	N/A	34.42%	14 Years

Latest MKKGY, ZTS, TAK, and DSNKY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
MKKGY Merck KGaA	0.23	1.31	0.83
TAK Takeda Pharmaceutical	0.60	1.16	0.59
ZTS Zoetis	1.05	1.76	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	0.10%
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	N/A
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
MKKGY Merck KGaA	62,557	646.21 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
ZTS Zoetis	13,800	443.18 million	442.39 million	Optionable

MKKGY, ZTS, TAK, and DSNKY Headlines

Recent News About These Companies

Zoetis Inc. $ZTS Shares Purchased by Capital Analysts LLC

August 22 at 6:29 AM | marketbeat.com

Erste Asset Management GmbH Has $17.06 Million Stock Position in Zoetis Inc. $ZTS

August 22 at 6:28 AM | marketbeat.com

Hsbc Holdings PLC Sells 16,056 Shares of Zoetis Inc. $ZTS

August 22 at 5:20 AM | marketbeat.com

Bowen Hanes & Co. Inc. Has $5 Million Stake in Zoetis Inc. $ZTS

August 21 at 7:07 AM | marketbeat.com

Credit Agricole S A Cuts Stock Position in Zoetis Inc. $ZTS

August 21 at 6:51 AM | marketbeat.com

Van Lanschot Kempen Investment Management N.V. Cuts Position in Zoetis Inc. $ZTS

August 21 at 6:37 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Lowers Stock Position in Zoetis Inc. $ZTS

August 21 at 6:15 AM | marketbeat.com

Andina Capital Management LLC Purchases New Stake in Zoetis Inc. $ZTS

August 21 at 6:05 AM | marketbeat.com

Texas Capital Bank Wealth Management Services Inc Has $8.53 Million Stock Holdings in Zoetis Inc. $ZTS

August 21 at 5:55 AM | marketbeat.com

Bank OZK Raises Stake in Zoetis Inc. $ZTS

August 21 at 5:45 AM | marketbeat.com

1,821 Shares in Zoetis Inc. $ZTS Acquired by Financial Advisors Network Inc.

August 21 at 5:36 AM | marketbeat.com

Wellington Management Group LLP Sells 893,168 Shares of Zoetis Inc. $ZTS

August 21 at 5:27 AM | marketbeat.com

Korea Investment CORP Reduces Stock Position in Zoetis Inc. $ZTS

August 21 at 5:21 AM | marketbeat.com

Northern Trust Corp Has $1.07 Billion Stock Holdings in Zoetis Inc. $ZTS

August 21 at 5:11 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Cresset Asset Management LLC

August 21 at 4:35 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Acquired by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

August 20 at 9:12 AM | marketbeat.com

Quantbot Technologies LP Purchases 37,334 Shares of Zoetis Inc. $ZTS

August 20 at 8:24 AM | marketbeat.com

Qtron Investments LLC Buys 3,375 Shares of Zoetis Inc. $ZTS

August 20 at 7:56 AM | marketbeat.com

Northwest & Ethical Investments L.P. Lowers Stock Holdings in Zoetis Inc. $ZTS

August 20 at 6:32 AM | marketbeat.com

Raymond James Financial Inc. Boosts Stock Holdings in Zoetis Inc. $ZTS

August 20 at 6:06 AM | marketbeat.com

Zoetis Inc. (ZTS) Announces Issuance of Senior Notes Totaling $1.85 Billion

August 18, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MKKGY, ZTS, TAK, and DSNKY Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$25.48 +0.18 (+0.71%)

As of 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Merck KGaA OTCMKTS:MKKGY

$26.33 +0.45 (+1.74%)

As of 03:55 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Takeda Pharmaceutical NYSE:TAK

$15.50 +0.19 (+1.26%)

Closing price 03:59 PM Eastern

Extended Trading

$15.01 -0.49 (-3.18%)

As of 05:05 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$156.32 +0.71 (+0.45%)

Closing price 03:59 PM Eastern

Extended Trading

$156.59 +0.27 (+0.17%)

As of 05:18 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time